KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Enterprise Value: 2009-2025

Historic Enterprise Value for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $7.9 billion.

  • Halozyme Therapeutics' Enterprise Value rose 19.61% to $7.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 billion, marking a year-over-year increase of 13.85%. This contributed to the annual value of $5.5 billion for FY2024, which is 20.68% up from last year.
  • As of Q3 2025, Halozyme Therapeutics' Enterprise Value stood at $7.9 billion, which was up 34.37% from $5.9 billion recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Enterprise Value ranged from a high of $7.9 billion in Q3 2025 and a low of $4.4 billion during Q2 2023.
  • Moreover, its 3-year median value for Enterprise Value was $5.5 billion (2024), whereas its average is $5.6 billion.
  • As far as peak fluctuations go, Halozyme Therapeutics' Enterprise Value spiked by 130.13% in 2021, and later plummeted by 37.98% in 2023.
  • Halozyme Therapeutics' Enterprise Value (Quarterly) stood at $4.9 billion in 2021, then soared by 49.00% to $7.3 billion in 2022, then plummeted by 37.98% to $4.5 billion in 2023, then grew by 20.68% to $5.5 billion in 2024, then grew by 19.61% to $7.9 billion in 2025.
  • Its Enterprise Value was $7.9 billion in Q3 2025, compared to $5.9 billion in Q2 2025 and $7.1 billion in Q1 2025.